Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elfrida R Grant

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell deathElfrida R Grant, Adrienne E Dubin, Sui-Po Zhang, et al.
Neurobiology of Disease|December 4, 2002
Apolipoprotein E protects against NMDA excitotoxicityMitsuo Aono, Yoonki Lee, Elfrida R Grant, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2003
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic propertiesKenneth J Valenzano, Elfrida R Grant, Gang Wu, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacology and Experimental Therapeutics|December 26, 2001
Simultaneous intracellular calcium and sodium flux imaging in human vanilloid receptor 1 (VR1)-transfected human embryonic kidney cells: a method to resolve ionic dependence of VR1-mediated cell deathElfrida R Grant, Adrienne E Dubin, Sui-Po Zhang, et al.
Neurobiology of Disease|December 4, 2002
Apolipoprotein E protects against NMDA excitotoxicityMitsuo Aono, Yoonki Lee, Elfrida R Grant, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 2, 2003
N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine -1(2H)-carbox-amide (BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. in vitro characterization and pharmacokinetic propertiesKenneth J Valenzano, Elfrida R Grant, Gang Wu, et al.
Pageof 1